3.0
12 Aug 2024
Current employee, more than 8 years
Holzkirchen
Recommend
CEO approval
Business outlook
Pros
- Great home office policy, good pay, canteen
Cons
- Company is struggling to find its on way after the Spin off from Novartis - Lots of budget cuts and headcount reducation at the moment - Hard to move on the career ladder